

RECEIVED
CENTRAL FAX CENTER

MAY 24 2004

OFFICIAL


Re: U.S. Patent Application No. 10/057,409 filed 01/23/2002
Title: Localized Myocardial Injection Method for Treating Ischemic Myocardium
First Inventor: Maria Palasis
Examiner: Ram R. Shukla Group Art Unit: 1632
Attorney Docket No.: 104914-132

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office to:

TC 1600 Before Final (703) 872-9306

on 05/24/2004
Date



Signature

M. Lisa Wilson

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify
each submitted paper.

Document

No.
Pgs.

Petition for Extension of Time (4 months)
Response

1
34 (MAY)

Total Number of Pages (including this Certificate of Transmission)

56
(MAY)

PATENT
Docket No. 104914.132 US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED
CENTRAL FAX CENTER**

MAY 24 2004

Applicant: Palasis)


Serial No.: 10/057,409)

Filing Date: January 23, 2002)

For: Localized Myocardial Injection)
Method for Treating Ischemic Myocardium)

Group Art Unit: 1632

Examiner: Shukla, Ram R.

OFFICIALCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE

In response to the Communication mailed May 18, 2004, indicating that Applicant's Response and Preliminary Amendment, filed February 23, 2004 ("Response") was not fully responsive to the restriction requirement and further requesting Applicant additionally elect a species for prosecution, Applicant hereby provisionally elects, with traverse, the species (1) for Claims 5, 7, 25, 42 and 44 to be VEGF; (2) for Claim 27 to be VEGF; (3) for Claims 30 and 32 to be the cTNC promoter; and (4) for Claims 13 and 50 to be stem cells

REMARKS

The Office Action of December 22, 2003 ("Action"), set forth a five-way restriction requirement. The Examiner indicated the claims of Group I linked the inventions of Groups I-V. In this regard, the subject matter of Group I is directed to a method of delivering a therapeutic agent into an ischemic heart at a specific location, namely by intramyocardial delivery of the